MultiCell Technologies Inc (MCET)

[simon wagstaff]

yeah, look at the most recent filing

Nine Months Ended August 31, 2014 Compared to the Nine Months Ended August 31, 2013

Revenue. Total revenue for the nine months ended August 31, 2014 and August 31, 2013 was $36,988. All of the revenue for the nine months ended August 31, 2014 and August 31, 2013 is from the amortization of deferred revenue under license agreements with Corning and Pfizer.

Operating Expenses. Total operating expenses for the nine months ended August 31, 2014 were $517,679, compared to operating expenses for the nine months ended August 31, 2013 of $1,018,548, representing a decrease of $500,869. This decrease was due to the reversal of $461,000 of stock-based compensation and a decrease of $99,963 in the recognition of other stock-based compensation, offset by an increase of $59,174 in professional and consulting fees and a net increase in other operating expenses of $920.